Mr. Jim Gilligan reports
TRYP THERAPEUTICS APPOINTS NEW CHIEF OPERATING OFFICER
Inc. has appointed Sid Taubenfeld, a seasoned executive with health care and biotech expertise, to the company's senior leadership team as chief operating officer.
Mr. Taubenfeld is a forward-thinking leader with over 20 years of significant experience in senior leadership roles and a deep understanding of scientific, financial and commercial strategy. Most recently, he served as the chief executive officer of Tikun Olam Pharma (TOP), a leading medical cannabis company based in Israel.
"Sid brings to his new role a wealth of expertise in building and growing emerging biotech companies and a strong reputation for developing people and inspiring teams," said Jim Gilligan, interim CEO and chief scientific officer of Tryp Therapeutics. "Furthermore, his national and international experience will be a valuable asset as we continue to drive growth through our clinical trials, filed patents and previously announced strategic actions."
Mr. Taubenfeld's primary responsibilities will include developing the organization's long-term vision and strategy alongside the CEO and board; ensuring that the company operates effectively and efficiently in all areas; and helping ensure a high-performing portfolio and psychedelic medicine advancements at Tryp.
Previously, Mr. Taubenfeld gained extensive pharmaceutical experience in a variety of executive management roles in the United States and Israel. He graduated from Brooklyn College of Pharmacy with a BS in pharmacy and completed his graduate studies at New York Medical College in the area of pharmacology.
About Tryp Therapeutics Inc.
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp's psilocybin-for-neuropsychiatric disorders (PFN) program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain and other indications. The company has begun enrolling patients in its phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience.
We seek Safe Harbor.
© 2022 Canjex Publishing Ltd. All rights reserved.